icon-    folder.gif   Conference Reports for NATAP  
  Back grey_arrow_rt.gif
Patient Satisfaction, Tolerability and Acceptability of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting Therapy in HIV-1-Infected Adults: LATTE-2 Week 96 Results
  Reported by Jules Levin
Miranda Murray,1Federico Pulido,2Anthony Mills,3Moti Ramgopal,4Roger LeBlanc,5Hans Jaeger,6Vasiliki Chounta,1David Dorey,7Sandy Griffith,8Joseph Mrus,8Viviam Canon,9David Margolis,8William Spreen8
1ViiV Healthcare, Brentford, UK; 2Hospital Universitario 12 de Octubre, Madrid, Spain; 3Southern California Men's Medical Group, West Hollywood, CA, USA; 4Midway Immunology and Research Center, Fort Pierce, FL, USA; 5Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada; 6MUC Research GmbH/MVZ Karlsplatz, Munich, Germany; 7GlaxoSmithKline, Mississauga, Ontario, Canada; 8ViiV Healthcare, Research Triangle Park, NC, USA; 9Janssen Pharmaceutica NV, Beerse, Belgium